DNBC-FINANCIAL-GROUP
13.4.2022 11:24:09 CEST | Business Wire | Press release
Sending money abroad has traditionally been an arduous and expensive task that frustrates users. Plus with the post-pandemic changes, people now need a faster yet cheaper contactless money transfer solution that can be done quickly on a mobile. That leads to the demand for payment apps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005433/en/
But which ones are the best international payment apps ? That depends. The best payment apps are the ones that work best for your business.
DNBCnet App - Powered by the leading Digital Banking Firm DNBC
Digital banking firm DNBC was founded by Le Hung Anh in 2017, professionally known as Jimmy Lee, headquartered in Singapore.
With the mission to support enterprises as well as individuals in financial transactions over the world, DNBC has developed the DNBCnet app in order to make the banking process easier yet cheaper by adapting more innovative changes right on the app.
“DNBCnet is an all-in-one tool for any user who wants to conduct international transactions, manage and control the cash flow of their business,” said Jimmy Lee, Founder & CEO of DNBC.
DNBCnet App offers exceptional benefits
Best for corporate international money transfers
When it comes to international payments , companies just want to make quick transactions while keeping the costs as low as possible.
It can be difficult to find a provider that offers quick transfers and low fees. But if you want to keep your business straightforward, you don’t have to look very far because DNBC business accounts will fit the bill.
“If you structure payments properly, digital banking can create more predictable cash flow over the life of your business,” said CEO Jimmy Lee.
Fastest ways to send money abroad
When sending money globally, an important factor besides fees is the speed. Speedy transfer will accelerate the business, otherwise it will slow down the whole operation significantly.
With DNBCnet app , recipients will get the fund instantly if transferred in DNBC network. It only takes 1-2 business days to send to someone outside the system.
Ease of use
DNBCnet works as a mobile app, the signing up process can be done quickly with a few simple steps. It owns a seamless visual interface which allows users to handle payments in no time.
On top of that, you can keep track of your transfer and get updates along the way, so you’re always in the loop about your funds.
Utmost safety for mobile banking
Security is a must for any financial app . DNBC has raised its standard by adopting the latest technology such as two-factor authentication , data encryption for every transaction.
That will help protect account information and transactions to the fullest extent preventing any potential frauds for customers and businesses.
As a bonus perk
Besides the core function, DNBCnet also adds up a number of accompanying features to make it even more favorable. Users now can also check real-time exchange rate information, view financial statistics by charts, send mobile top up and many more.
Level up your payment practice with DNBCnet app
One of the key benefits of digital banking apps is that they allow users to manage payments anywhere and anytime. With that, business owners can focus on delivering services, not bothering with the payment process .
DNBCnet app offers exceptional convenience and transparency to its users. Via smartphones, you can find the IOS version for mobile banking on the App Store or mobile banking app for Android in the Google Store. Or simply search for DNBCnet .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005433/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
